We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genus Plc | LSE:GNS | London | Ordinary Share | GB0002074580 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-22.00 | -1.23% | 1,765.00 | 1,783.00 | 1,788.00 | 1,813.00 | 1,780.00 | 1,796.00 | 95,844 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 689.7M | 33.3M | 0.5043 | 35.36 | 1.18B |
Date | Subject | Author | Discuss |
---|---|---|---|
16/11/2012 08:45 | 0707 GMT [Dow Jones] Goldman Sachs upgrades Genus (GNS.LN) to conviction buy from buy but cuts price target to 2100p from 2200p. The de-rating of the shares since last week's trading update creates an attractive entry point, says GS. Says the growth opportunity in porcine products in China remains intact. Over the mid term, Goldman expects sales growth to accelerate as recent investments in developing the company's emerging markets business bear fruit. Shares closed Thursday at 1284p. (michele.maatouk@dow | ukinvestor220 | |
14/11/2012 19:26 | Re entry target £12 or £10 not seen the bottom yet!! | dvarty | |
13/11/2012 21:46 | huttonr & clintonville -- certainly the demand for consumer products such as pork will carry on rising in china and the far east baring disaster --- it's just that the share price rise of genus has really been excessive and more to do with selling the story than the fact, and extreme supply constraints and I'm grateful for that: but this type of demand always means boom and bust -- there is no middle way --- so i think the sell off will probably continue very sharply for a good while - this doesn't mean that they aren't a good company and that there isn't a market for their excellent products. I won't go short because i'm a coward but as things stand i will leave it a while before reevaluating. Good luck! | planckfund2 | |
13/11/2012 17:25 | A few comments - partly to see what other people think. It seems to me that the share price got a bit ahead of itself during the last month or so and we have now got back to a reasonable level. Looking at the rise since January, we have had a good run and hopefully will stay around this level for a while. The so-called Chinese slowdown looks more like a little reduction in the growth rate but the real change in demand for meat in China - pork especially - seems likely to continue as the pace of social change continues. The company appears to be doing the right things with their current emphasis on China which will make up for a possible mild slowdown elsewhere. However, the basic selling point for Genus is the yield improvement and they do seem to be one of the market leaders here. | huttonr | |
12/11/2012 10:12 | The economic slowdown is'nt going to stop people eating meat. | clintonville | |
08/11/2012 23:13 | but what do i know? | planckfund2 | |
08/11/2012 23:13 | chinese slowdown now makes this one a big sell for me | planckfund2 | |
08/11/2012 23:06 | chinese slowdown now makes this one a sell for me | planckfund2 | |
08/11/2012 14:18 | Clintonville, see to-days IMS....head winds. | bobdouthwaite | |
08/11/2012 12:05 | Why is the share dropping by 3.64% at 12pm I can't find any adverse news regarding the company.Does anyone know why? | clintonville | |
20/9/2012 21:22 | 1475p all time high print and closing figure today. 1600p target. | matt123d | |
18/5/2012 14:55 | What The Analysts Say MORGAN STANLEY SAYS... Overweight. Our bull case valuation - at 1,790p - assumes that Genus meets its aspirational earnings growth target of 15 per cent year on year throughout the decade. But there are strong global themes to drive that thesis. These include population growth and rising food demand, industrialised farming methods and sector consolidation among food producers, as well as emerging markets growth, coupled with a shift there towards western-style diets - that is, more dairy and meat consumption. Expect EPS to rise to 52p for the year to end-June 2012, from 44.1p in 2011. PEEL HUNT SAYS... Buy. The share price rating does look full, but the longer-term growth opportunity remains compelling. Genus is the global market leader in this business and is increasing its competitive advantage. In fact, the company boasts a number of strategic advantages, such as its genetic lead and international presence. Moreover, research and development initiatives provide the opportunity for step-changes in market share and profitability. Genus looks increasingly well positioned to take advantage of growth opportunities. The price target stands at 1,500p and expect adjusted EPS for end-June 2012 of 50.8p. Read the full article here: P.S. Here's a couple of links about SCLP, one of the hottest stocks at the moment: | northernlass | |
18/5/2012 14:53 | GENUS AIMS TO PIG OUT IN CHINA In the porcine market in China, Genus is already in discussions with a number of leading integrated pig producers looking to improve the quality of their genetics and expand their production. These discussions envisage the creation of joint ventures with these producers who will use a significant proportion of the breeding animals produced by the joint venture to build their own pig production system. Genus has concluded that this type of structure will enable the group to provide its genetics in a manner that protects its intellectual property and enables the introduction of a royalty model that Genus already operates in its porcine business across other geographies. Read the full story here: | northernlass | |
18/5/2012 14:52 | Interims + Strategy Update Genus Provides Interim Management Statement, Strategy Update Genus Plc (GNS.L) issues its interim management statement for the period from 1 January 2012 and also an update on the Group's strategy that has the objective of establishing the framework to enable an improving rate of growth from 2014 onwards. During the period since 1 January 2012, Genus has continued to trade in line with the board's view and ahead of the prior year. Overall demand for Genus' products and services has continued broadly in line with that experienced in the first half of the current financial year. In North America, the porcine business has sustained its positive momentum with volumes up by 10% leading to a similar rise in royalty income. Improved average selling prices and tight cost control have enabled bovine profits to progress despite volumes at broadly the same level as last year. Source: | northernlass | |
03/5/2012 13:02 | I am thinking of buying the shares. What price do you think I should pay for it? | clintonville | |
27/4/2012 23:17 | PE looking very toppy indeed ....time to short getting closer Hope it helps | sanks | |
27/4/2012 18:01 | think there is an investor day soon - also liberum bullish note. | edwardt | |
27/4/2012 08:49 | Whoosh another break out!! Anyone know why on no news? | dvarty | |
05/3/2012 17:49 | Encouraging news for Genus in China: | bobdouthwaite | |
24/2/2012 15:54 | Wow - breakout! | ranger101 | |
11/10/2011 12:21 | i'm long and following this share - it's gone up a fair bit over the last few years but undoubtably has room to go much further. Right place, right time.... | planckfund2 | |
03/10/2011 19:48 | A big pharma will licence there drugs or will do a takeover of Verona pharma listed on Aim. | aimshares | |
16/5/2011 22:11 | correct ...... ;=) | squire007 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions